Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases
US11420936B2 · kind B2 · utility
2Cited by
6References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 3, 2022 |
| Grant date | Aug 23, 2022 |
| Priority date | — |
| Expiry date | Mar 3, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2603/10
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present disclosure is directed certain Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and their use in the treatment of diseases mediated by HIF-2α such as cancer. Also provided is the use of HIF-2α inhibitors in combination with a poly (ADP-ribose) polymerase (PARP) inhibitor. In particular, the present disclosure is directed to methods for the treatment of cancers using a HIF-2α inhibitor in combination with a PARP inhibitor and pharmaceutical compositions comprising the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.